Engineered proteases for proteomics

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$199,999.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
1R43RR025973-01
Agency Tracking Number:
RR025973
Solicitation Year:
2009
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2009-2
Small Business Information
POTOMAC AFFINITY PROTEINS, LLC
POTOMAC AFFINITY PROTEINS, LLC, 11305 DUNLEITH PL, NORTH POTOMAC, MD, 20878
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
N
Woman Owned:
Y
Duns:
193771347
Principal Investigator:
BIAO RUAN
(301) 610-9687
RUAN@UMBI.UMD.EDU
Business Contact:
BONNIE BRYAN
(301) 610-9687
potomac_affinity@msn.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Proteomics is a rapidly expanding field but current methodologies remain inadequate for achieving its full potential. The most basic enzymological tool for characterizing proteins is the protease. Proteases are already an essential part of proteomic analysis but more sophisticated tools are needed to identify low abundance proteins in highly complex samples. We have engineered a prototype restriction protease which is active in denaturing conditions and which cuts specifically at a well-defined cognate sequence motif. Our basic innovation would be the ability to parse a proteome into sequence-edited slices and to detect these edited portions with high resolution and high sensitivity. In Phase I we propose to test the prototype restriction protease for its suitability in proteomic analysis and to implement a novel directed evolution methodology for the selection of proteases that cut new sequence motifs. The long range objective is to develop a sophisticated set of protease tools to facilitate proteomic analysis in the way restriction endonucleases have facilitated genomic analysis. PUBLIC HEALTH RELEVANCE: The complex and dynamic nature of proteomes make them rich with useful information but difficult to characterize. Our long-range objective is to develop a sophisticated set of protease tools to facilitate proteomic analysis in the way restriction endonucleases have facilitated genomic analysis. Better proteomic tools will lead to earlier detection of disease states, better treatments, better predictability of the effects of various treatments, and the development of individualized therapies.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government